<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220103</url>
  </required_header>
  <id_info>
    <org_study_id>2185</org_study_id>
    <nct_id>NCT00220103</nct_id>
  </id_info>
  <brief_title>Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma</brief_title>
  <official_title>Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of epirubicin, cisplatin and capecitabine as
      neoadjuvant therapy prior to radical resection in patients with newly diagnosed operable
      oesophageal adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate assessed by CT and EUS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related toxicity including peri-operative complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of dysphagia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of treatment failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the value of high resolution MRI to depict response to treatment and compare it with EUS and histopathology</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Adenocarcinoma of Oesophagus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin, capecitabine, cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  Histologically verified adenocarcinoma of the thoracic oesophagus or type 1, 2 and 3
             tumours of the oesophagogastric junction (type 1 refers to lower oesophageal, type 2
             refers to cardial and type 3 refers to subcardinal cancers).

          -  AJCC Stage II-III (T2-3 N0-1 M0) (28), as assessed by spiral or multi-slice CT and
             endoscopic ultrasound, where primary surgery would be considered with curative intent.

          -  No previous chemotherapy, radiotherapy or other investigational drug treatment for
             this indication.

          -  WHO performance status 0,1 or 2.

          -  Adequate bone marrow function with platelets &gt; 100 x 109/l; WBC &gt; 3 x 109/l;
             neutrophils &gt; 1.5 x 109/l at the time of study entry.

          -  Serum bilirubin &lt; 35 mol/l.

          -  Serum creatinine &lt; 180 mol/l and measured creatinine clearance over 60ml/min.

          -  No concurrent uncontrolled medical condition.

          -  No previous malignant disease other than non-melanotic skin cancer or carcinoma in
             situ of the uterine cervix in the last 10 years.

          -  Life expectancy &gt; 3 months.

          -  Adequate contraceptive precautions if relevant.

          -  Informed written consent.

        Exclusion Criteria:

          -  The presence of locally advanced or metastatic disease precluding curative surgical
             resection (T4 or Stage IV or M1a-b)

          -  Total dysphagia (O'Rourke's swallowing function scoring system 5) precluding
             swallowing of capecitabine even when crushed

          -  Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent.

          -  Patients with disease in any of the following areas on the basis of CT scan and/or
             endoscopic ultrasound:

               -  Evidence of liver, lung or other distant metastases

               -  Para-aortic/coeliac lymphadenopathy &gt; 1cm diameter on CT, &gt; 6mm diameter on EUS

               -  Invasion of airways, aorta, pericardium, or lung

          -  New York Heart Association classification Grade III or IV.

          -  Uncontrolled angina pectoris.

          -  Pregnancy or breast feeding.

          -  Impaired renal function with measured creatinine clearance less than 60 ml/min.

          -  Known malabsorption syndromes.

          -  Patients with a known hypersensitivity to 5-FU or with a dihydropyrimidine
             dehydrogenase (DPD) deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cunningham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 15, 2009</last_update_submitted>
  <last_update_submitted_qc>December 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jane Lawrence</name_title>
    <organization>Royal Marsden NHS Foundation Trust</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

